RecruitingEarly Phase 1NCT06995976

Dosimetry and Preliminary Clinical Application Study of a Novel Probe Targeting CD73

Sponsor

First Affiliated Hospital of Fujian Medical University

Enrollment

30 participants

Start Date

Mar 1, 2025

Study Type

INTERVENTIONAL

Conditions

Malignant Tumour

Summary

As a new CD73-targeted PET radiotracer, 68Ga-dPNE, is promising as an excellent imaging agent applicable to various cancers. In this study, we observed the safety, biodistribution and radiation dosimetry of 68Ga-dPNE in human volunteers. Furthermover, we conducted a comparative analysis of 68Ga-dPNE and 18F-FDG imaging to assess both the radiation dosimetry and diagnostic efficacy of 68Ga-dPNE.

Eligibility

Min Age: 18 YearsMax Age: 90 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called 18F-FDG and a drug called 68Ga-dPNE for people with malignant tumour. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 90 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUG68Ga-dPNE

Intravenous injection of 68Ga-dPNE. 68Ga-dPNE PET/CT will be used to detect tumors.

DRUG18F-FDG

Intravenous injection of 18F-FDG.18F-FDG PET/CT will be used to detect tumors.

Locations(1)

The First Affiliated Hospital of Fujian Medical University

Fuzhou, Fujian, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06995976